Hemodynamic characteristics of vasopressin in dogs with severe hemorrhagic shock.
The effect of vasopressin was compared with that of the established vasopressor epinephrine in experimentally induced hemorrhagic shock. After rapid crystalloid resuscitation in a ratio of three volumes of 0.9% saline to one volume of blood (3:1 crystalloid resuscitation), six dogs were given 0.4 IU/kg vasopressin and another six dogs were given 0.1 mg/kg epinephrine. Five dogs in the control group were given fluid resuscitation in the same manner as above without administration of any drugs. Administration of vasopressin increased diastolic arterial pressure (DAP) from 45.0 +/- 4.9 to 91.2 +/- 9.6 mmHg within 5 min, compared with epinephrine from 46 +/- 4.0 to 51.8 +/- 7.7, and control from 47.3 +/- 7.5 to 46.3 +/- 7.3. Systolic arterial pressure (SAP) did not increase significantly following vasopressin compared with epinephrine and control group. Results of DAP and systemic vascular resistance index (SVRI) suggested that vasopressin administration was vasoconstrictive after fluid resuscitation in decompensatory hemorrhagic shock in dogs, whereas epinephrine did not compared with control. In addition, epinephrine did not affect the cardiac index (CI) and SVRI, while a significant decrease in CI and increase in SVRI were observed in vasopressin group. The pressor effect of epinephrine in the vascular system was abrupt and only lasted a short period of time (within 5 min), while that of vasopressin was steady and lasted for more than 1 hr, especially regard to in DAP. When compared with epinephrine, vasopressin can be a more effective and safer choice in patients with severe hemorrhagic shock.
Yoo
Jong-Hyun
JH
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Kwanak-gu, Seoul, South Korea.
Kim
Min-Su
MS
Park
Hee-Myung
HM
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D008297:Male; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000662:veterinary*; D013566:Sympathomimetics / Q000494:pharmacology / Q000627:therapeutic use; D014667:Vasopressins / Q000494:pharmacology* / Q000627:therapeutic use*
D013566:Sympathomimetics; D014667:Vasopressins; D004837:Epinephrine